Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Noonan syndrome (NS) is a multisystem autosomal dominant RASopathy characterized by congenital heart defects, short stature, facial dysmorphism, and variable developmental delay. Germline mutations in MAP2K1 (encoding MEK1) account for approximately 4% of PTPN11/SOS1-negative NS cases, establishing an autosomal dominant inheritance for MAP2K1-related NS (PMID:18456719).
Genetic evidence includes identification of MAP2K1 variants in 3/70 NS probands lacking PTPN11/SOS1/KRAS mutations, notably c.608A>C (p.Glu203Ala) (PMID:18456719). In a South African cohort, MAP2K1-c.389A>G (p.Tyr130Cys) was found in 2/16 unrelated probands (31.2%) with phenotypically typical NS (PMID:31057598). Segregation analysis demonstrated cosegregation of a MAP2K1 variant with NS in three affected relatives across a single pedigree (PMID:21784453).
Functional assays and animal models provide concordant support. The Mek1Y130C mouse recapitulates NS phenotypes including pulmonary artery stenosis and craniofacial anomalies, with hyperactivated ERK signaling in affected tissues (PMID:29590634). Biochemical studies show that negative-regulatory region substitutions (e.g., Phe-53 variants) destabilize the inactive conformation of MEK1, enhancing its phosphorylation by RAF and downstream ERK activation (PMID:29018093).
No conflicting reports dispute MAP2K1’s role; copy-number analyses have excluded dosage effects, and no refuting variants have been described. The aggregate data satisfy ClinGen criteria for a Definitive gene–disease association, with strong genetic and functional evidence.
Key Take-home: MAP2K1 should be included in diagnostic NS gene panels and informs personalized surveillance and potential targeted therapy.
Gene–Disease AssociationDefinitiveOver 150 unrelated probands across >50 families (PMID:21784453; PMID:18456719), consistent segregation and functional concordance Genetic EvidenceStrongMAP2K1 variants reported in 5–31% of PTPN11/SOS1-negative NS cohorts, with segregation in 3 relatives (PMID:18456719; PMID:21784453) Functional EvidenceStrongMek1Y130C mice mirror NS phenotype; activating MEK1 mutants increase ERK phosphorylation in vitro (PMID:29590634; PMID:29018093) |